Actively Recruiting
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Led by Liverpool University Hospitals NHS Foundation Trust · Updated on 2024-08-30
282
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
Sponsors
L
Liverpool University Hospitals NHS Foundation Trust
Lead Sponsor
K
Kidney Research United Kingdom
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to assess a new test to detect antibodies which may form following kidney transplant. These antibodies can be difficult to detect as they do not cause any symptoms but can lead to kidney damage. A new blood test will be performed alongside existing antibody tests to see how well the test functions in comparison and to see how well it is able to distinguish between inflammation caused by antibodies and other sorts of inflammation such as a urinary tract infection. The investigators also want to determine whether it is predictable whom will develop antibodies after a transplant and use these results to change the current way patients are monitored for antibodies after receiving a transplant. In addition to this, the investigators want to establish if patients over 60 years of age are relatively protected against immunological events such as rejection compared to patients who are under 60 years of age. The results could potentially lead to using a different immunosuppression regime based on which population age group patients belong to and lowering the risks associated with these drugs.
CONDITIONS
Official Title
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients transplanted within 6 to 12 months (retrospective recruitment)
- Patients admitted for kidney transplant or within the first 6 months following transplant (prospective recruitment)
- Patients must have capacity to provide informed consent
- Patients must have received a high-risk transplant defined as level 4 mismatch, cRF >20%, second or subsequent transplant, ABO or HLA incompatible
- Any adult patient with capacity undergoing, or within 72 hours of, a kidney transplant
- Any adult patient with capacity undergoing, or within 72 hours of, a kidney transplant who is unsensitized pre-transplant
You will not qualify if you...
- Transplanted for longer than 12 months (cf-DNA arm)
- Low risk transplants (cf-DNA arm)
- Patients lacking capacity
- Patients transplanted longer than 2 weeks (Older Age Immunological Events and Predictive models)
- Sensitized patients (Predictive models)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L7 8YE
Actively Recruiting
Research Team
G
George E Nita, MBChB MSc MRCSEd
CONTACT
P
Petra M Goldsmith, MBBChir PhD FRCS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here